CoChat
Sign Up
Cited by 64

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer

Tomek, Katharina, Wagner, Renate, Varga, Franz, Singer, Christian F., Karlic, Heidrun, Grunt, Thomas W.·2011·Molecular Cancer Research
DOI 10.1158/1541-7786.mcr-10-0467

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Aberrations within the phosphoinositide-3-kinase (PI3K) pathway occur in greater than 45% of ovarian carcinomas. The PI3K cascade transmits signals from ErbB receptors downstream to S6 and 4EBP1, which are involved in protein biosynthesis. Many ovarian carcinomas reveal hyperactivation of ErbB1 (epidermal growth factor receptor) or ErbB2 (HER2/neu). Unfortunately, the benefit of anti-ErbB drugs is yet rather limited in ovarian carcinomas. Thus, novel targeting strategies are needed for ovarian carcinomas. The lipogenic enzyme fatty acid synthase (FASN) is overexpressed in approximately 80% of ovarian carcinomas. It stimulates cell growth and signifies poor prognosis. FASN inhibition impedes (ErbB) membrane receptor signaling and sensitizes cells against anti-ErbB drugs. Here, we show that the FASN inhibitor C75 and FASN-targeting siRNAs abrogate growth, induce apoptosis, and downregulate phosphorylation/expression of the PI3K effectors AKT, mTOR, p70S6K, S6, and 4EBP1. In contrast, FASN inhibition impairs expression but only weakly affects phosphorylation of ERK1/2 mitogen-activated protein kinases in ovarian carcinoma cells. Cycloheximide-mediated blockade of protein translation reveals that C75- or FASN siRNA–induced shutdown of FASN accelerates decomposition of signaling proteins. This effect is caused by C75- or FASN siRNA–dependent stimulation of ubiquitination followed by lysosomal-autophagosomal proteolysis. In contrast, PI3K inhibitor LY294002 blocks phosphorylation but does not reduce expression/stability of PI3K effectors. Forced expression of hyperactive (HA) AKT1, unlike HA-MEK1, impairs the growth-inhibitory action of C75. We provide first evidence that the anticancer action of FASN inhibitors is at least partially mediated by drug-dependent proteolysis of PI3K effectors. FASN is a promising cancer target, whose inhibition not only abrogates lipogenesis, which is indispensable for cancer growth, but also downregulates oncogenic PI3K signaling. Mol Cancer Res; 9(12); 1767–79. ©2011 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-10-0467

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 36

  1. Gao, 2004, G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells, Am J Physiol Cell Physiol, 287, C281, 10.1152/ajpcell.00422.2003 · DOI
  2. Easton, 2006, mTOR and cancer therapy, Oncogene Rev, 25, 6436, 10.1038/sj.onc.1209886 · DOI
  3. Manning, 2002, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway, Mol Cell, 10, 151, 10.1016/S1097-2765(02)00568-3 · DOI · Paper page
  4. Graff, 2008, Targeting the eukaryotic translation initiation factor 4E for cancer therapy, Cancer Res, 68, 631, 10.1158/0008-5472.CAN-07-5635 · DOI
  5. Olayioye, 2000, The ErbB signalling network: receptor heterodimerization in development and cancer, EMBO J, 19, 3159, 10.1093/emboj/19.13.3159 · DOI
  6. de Graeff, 2008, The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer, Br J Cancer, 99, 341, 10.1038/sj.bjc.6604471 · DOI
  7. Lassus, 2004, ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma, Gynecol Oncol, 92, 31, 10.1016/j.ygyno.2003.10.010 · DOI
  8. Lassus, 2006, Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma, J Mol Med, 84, 671, 10.1007/s00109-006-0054-4 · DOI
  9. Nielsen, 2004, Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer, Int J Gynecol Cancer, 14, 1086, 10.1111/j.1048-891X.2004.14606.x · DOI
  10. Reibenwein, 2008, Targeting signaling pathways in ovarian cancer, Expert Opin Ther Targets, 12, 353, 10.1517/14728222.12.3.353 · DOI
  11. Alò, 2000, Immunohistochemical study of fatty acid synthase in ovarian neoplasms, Oncol Rep, 7, 1383
  12. Gansler, 1997, Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival, Hum Pathol, 28, 686, 10.1016/S0046-8177(97)90177-5 · DOI
  13. Wang, 2005, Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells, Oncogene, 24, 3574, 10.1038/sj.onc.1208463 · DOI
  14. Pizer, 1996, Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer, Cancer Res, 56, 1189
  15. Grunt, 2009, Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells, Biochem Biophys Res Comm, 385, 454, 10.1016/j.bbrc.2009.05.085 · DOI
  16. Grunt, 2007, Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways, J Cell Physiol, 211, 803, 10.1002/jcp.20990 · DOI
  17. Brünner-Kubath, 2011, The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells, Breast Cancer Res Treat, 129, 387, 10.1007/s10549-010-1232-1 · DOI
  18. Thupari, 2002, C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity, Proc Natl Acad Sci U S A, 99, 9498, 10.1073/pnas.132128899 · DOI
  19. Bentebibel, 2006, Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation, Biochemistry, 45, 4339, 10.1021/bi052186q · DOI · Paper page
  20. Puig, 2009, Novel inhibitors of fatty acid synthase with anticancer activity, Clin Cancer Res, 15, 7608, 10.1158/1078-0432.CCR-09-0856 · DOI
  21. Bandyopadhyay, 2006, Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells, Cancer Res, 66, 5934, 10.1158/0008-5472.CAN-05-3197 · DOI
  22. Adams, 2004, Development of the proteasome inhibitor Velcade (Bortezomib), Cancer Invest, 22, 304, 10.1081/CNV-120030218 · DOI
  23. Raben, 2009, Monitoring autophagy in lysosomal storage disorders, Methods Enzymol, 453, 417, 10.1016/S0076-6879(08)04021-4 · DOI
  24. Campbell, 2004, Mutation of the PIK3CA gene in ovarian and breast cancer, Cancer Res, 64, 7678, 10.1158/0008-5472.CAN-04-2933 · DOI
  25. Wu, 2005, Somatic mutation and gain of copy number of PIK3CA in human breast cancer, Breast Cancer Res, 7, R609, 10.1186/bcr1262 · DOI
  26. Little, 2007, Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells, Cancer Res, 67, 1262, 10.1158/0008-5472.CAN-06-1794 · DOI
  27. Dai, 2009, Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells, Int J Oncol, 34, 1749
  28. Loftus, 2000, Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors, Science, 288, 2379, 10.1126/science.288.5475.2379 · DOI · Paper page
  29. Flavin, 2010, Fatty acid synthase as a potential therapeutic target in cancer, Future Oncol, 6, 551, 10.2217/fon.10.11 · DOI
  30. Hennessy, 2005, Exploiting the PI3K/AKT pathway for cancer drug discovery, Nat Rev Drug Discov, 4, 988, 10.1038/nrd1902 · DOI
  31. Karbowniczek, 2006, Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization, J Biol Chem, 281, 25447, 10.1074/jbc.M605273200 · DOI
  32. Lu, 1998, Activation of protein kinase C triggers its ubiquitination and degradation, Mol Cell Biol, 18, 839, 10.1128/MCB.18.2.839 · DOI
  33. Bogusz, 2006, A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin–proteasome pathway, FEBS J, 273, 2913, 10.1111/j.1742-4658.2006.05304.x · DOI
  34. Wang, 2008, Regulation of ribosomal protein S6 kinases by ubiquitination, Biochem Biophys Res Comm, 369, 382, 10.1016/j.bbrc.2008.02.032 · DOI
  35. Gwalter, 2009, The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase, Int J Biochem Cell Biol, 41, 828, 10.1016/j.biocel.2008.08.018 · DOI
  36. Knowles, 2007, Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer, BMC Genomics, 8, 168, 10.1186/1471-2164-8-168 · DOI

Cited by

Sorted by citations

See all 64

Metadata

Authors
Tomek, K., Wagner, R., Varga, F., Singer, C. F., Karlic, H., & Grunt, T. W.
Venue
Molecular Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2011-12-01
Volume
9
Issue
12
Pages
1767-1779
ISSN
  • 1541-7786
  • 1557-3125
DOI
10.1158/1541-7786.mcr-10-0467
Cited by
64
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review